| 摘要 |
The present invention provides glucopyranosyloxypyrazole derivative of the formula (I) wherein R represents a hydrogen atom, alkyl group having 1 to 6 carbon atoms, acyl group having 2 to 7 carbon atoms, alkoxycarbonyl group having 2 to 7 carbon atoms, hydroxymethyl O substituted with acyl group having 2 to 7 carbon atoms, or O substituted with alkoxycarbonyl group having 2 to 7 carbon atoms, one of Q and T represents a group represented by the formula (A), wherein P represents a hydrogen atom, acyl group having 2 to 7 carbon atoms substituted with alkoxy group having 1 to 6 carbon atoms, with alkoxycarbonyl group having 2 to 7 carbon atoms, alkoxycarbonyl group having 2 to 7 carbon atoms substituted with alkoxy group having 1 to 6 carbon atoms; and second is alkyl group having 1 to 6 carbon atoms, eventually substituted with 1 to 3 halogen atoms; R2 represents a hydrogen atom, alkyl group having 1 to 6 carbon atoms, optionally substituted with 1 to 3 halogen atoms, alkoxy group having 1 to 6 carbon atoms, alkylthio group having 1 to 6 carbon atoms or a halogen; or pharmaceutically acceptable salts thereof. A pharmaceutical composition comprising this derivative. Said derivative or pharmaceutical composition for the use as a human SGL T2 inhibitor, an agent for the prevention or treatment of a disease associated with hyperglycemia such as diabetes and obesity. A pharmaceutical combinations comprising this derivative. |
